Loading news...
DXCM beats Q4 EPS estimates, posts 13% revenue growth and reiterates 2026 guidance as G7 15 Day rollout and margin gains drive momentum.
Insights from Frank Sands (Trades, Portfolio)' Fourth Quarter 2025 13F Filing Frank Sands (Trades, Portfolio) recently submitted the 13F filing for the fourth
Worldwide Revenue: $1.26 billion for Q4 2025, up 13% from Q4 2024.US Revenue: $892 million for Q4 2025, an increase of 11% from Q4 2024.International Revenue:
DexCom, Inc. (DXCM) Q4 2025 Earnings Call Transcript
DexCom (DXCM) came out with quarterly earnings of $0.68 per share, beating the Zacks Consensus Estimate of $0.65 per share. This compares to earnings of $0.45 per share a year ago.
Here's a look at the details in the report.
Medical device maker Dexcom beat Wall Street estimates for fourth-quarter results on Thursday, driven by robust demand for its continuous glucose monitoring systems.
SAN DIEGO--(BUSINESS WIRE)--Dexcom Reports Fourth Quarter and Fiscal Year 2025 Financial Results.
DexCom heads into Q4 earnings with easing G7 issues, improving supply chains and rebounding U.S. new customer starts lifting revenue outlook.
Evaluate the expected performance of DexCom (DXCM) for the quarter ended December 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Allianz Asset Management GmbH increased its stake in shares of DexCom, Inc. (NASDAQ: DXCM) by 84.2% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 103,317 shares of the medical device company's stock after buying an additional 47,234
AGF Management Ltd. bought a new position in DexCom, Inc. (NASDAQ: DXCM) in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 9,758 shares of the medical device company's stock, valued at approximately $657,000. Other institutional investors and hedge funds
Dexcom plans a nationwide AI upgrade to Stelo, adding a million-plus food database and smarter insights to improve glucose understanding and wellness goals.
DexCom (DXCM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
SAN DIEGO--(BUSINESS WIRE)--Dexcom, Inc. (Nasdaq:DXCM), the global leader in glucose biosensing, announced it will roll out an advanced AI-enabled enhancement to Stelo that will transform how users understand their glucose health and take steps in achieving their long-term health goals. The newest features will launch nationwide in the coming weeks. Last year, Dexcom introduced AI-driven Smart Food Logging in Stelo, the first over-the-counter glucose biosensor cleared1 by the FDA in the United.
Shareholders should contact the firm immediately as there may be limited time to enforce your rights. NEW YORK, Jan. 29, 2026 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of DexCom, Inc. (NASDAQ: DXCM) breached their fiduciary duties to shareholders.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Hussman Strategic Advisors Inc. purchased a new position in shares of DexCom, Inc. (NASDAQ: DXCM) in the undefined quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 42,000 shares of the medical device company's stock, valued at approximately $2,826,000. Several other institutional investors have also